SCIENCE
Why InSphero?
Enabling Technology
3D Select™ Process
Microtissue Formats
Organ-on-a-chip Systems
Organoid Shipping
RNA Sequencing
Publications
Peer-reviewed Papers
White Papers
Posters
Blog
Digital Media
Summer School
Video
Webinar
Seminars
APPLICATIONS
Application Overview
Liver Toxicology
DILI Prediction
Mechanistic Assays
Metabolic Disease
Diabetes & Islet Research
Liver Disease
Oncology
Efficacy Testing
Immuno-Oncology
PRODUCTS
3D InSight™ Platforms
Liver
Liver Disease
Steatosis
NASH
Liver Toxicology
Human
Animal
Islet
Human
Rat
Platform Add-Ons
3D Tumor models
Assay-ready Models
PDX Models
Custom Tumor Model Development
How to Order
SERVICES
Services Overview
In Vitro
Toxicology
14 Day Hepatotoxicity
Custom Mechanistic and Investigative Studies
Pancreatic Endocrine Toxicity
Diabetes and NASH Drug Discovery
Diabetes Drug Testing
NASH Drug Testing
Oncology Drug Discovery
Custom Tumor Models Development
Efficacy Testing
Combinatorial Drug Testing
Tumor Relapse Assay
Antibody Penetration
Immuno-Oncology
Get Started with InSphero
ABOUT
About InSphero
Leadership
Careers
Contact Us
Our Partners
Consortium
News & Events
Newsletter
Media Releases
Events, Fairs & Conferences
SUPPORT
Help Center
Production Schedule
BLOG
SHOP
PBMC co-culture
July 10, 2019
Disruptive 3D Cell Technology Drives Innovative Diabetes R&D at ADA2019
InSphero CEO Jan Lichtenberg reflects on ADA2019 and how InSphero is enabling T1D and T2D Discovery with our 3D InSight™ Diabetes Discovery Platform. Over the past few years, diabetes R&D
[…]
